FLT3 and acute myeloid leukemia: Similar results were reported with other FLT3 inhibitors used off label in a small subgroup of patients with relapsed/refractory FLT3 mutated AML in the DEC10-VEN trial.53 They included 10 patients who received sorafenib (n = 5), gilteritinib (n = 4), and midostaurin (n = 1).